The Work We Fund

Funded projects
Men's Health Partners
We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact.
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programs
Mental health and suicide prevention
“The number of men taking their own lives around the world is one of the biggest challenges of our time. Movember is working to ensure all men and boys look after their mental health and are comfortable to seek help when they’re struggling.”
Brendan Maher, Global Director, Mental Health and Suicide Prevention.
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programs.

Swiss Prostate Cancer Award - Pharmacological Inhibition of TRIM24 in Castrate Resistant Prostate Cancer: An effective tool towards the cure of advanced prostate cancer

Movember Funding to Date

EUR 200,000

What we seek to achieve

This project is investigating whether targeting a particular protein called TRIM24 could serve as a potential therapy for men with castrate resistant prostate cancer. The funded work will be conducted using pre-clinical models has implications for drug development, and if successful could lead to the initiation of clinical trials for men with advanced prostate cancer.

Implemented by
Movember Foundation
Project start date
October 2016
Project Status
In Progress

About the project

Professor Jean-Philippe Theurillat from the University of Lausanne will gather information on the activity of TRIM24 inhibitors in preclinical models of castration-resistant prostate cancer in view of applying this knowledge to clinical trials. Some preclinical models show exquisite susceptibility to TRIM24 inhibitors. This study aims to determine whether this observation is more generalizable across prostate cancer cell lines, or if distinct cell line traits predict sensitivity or resistance to TRIM24 inhibition. This may help to identify specific tumor patients in which TRIM24 inhibitors could be particularly effective and could potentially serve as a therapeutic target for these men.

Page 1 of 23